Trials / Completed
CompletedNCT03599986
Clinical Efficacy and Safety of Leflunomide in Egyptian Patients With Active Rheumatoid Arthritis
A Phase IV, Multi-Centric, Prospective, Observational Study to Assess the Clinical Efficacy and Safety of Leflunomide in Egyptian Patients With Active Rheumatoid Arthritis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 398 (actual)
- Sponsor
- Eva Pharma · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
A Phase IV, Multi-Centric, Prospective, Observational Study to Assess the Clinical Efficacy and Safety of Leflunomide in Egyptian Patients with Active Rheumatoid Arthritis. (CLEAR)
Detailed description
CLEAR is a phase IV, multi-centric, prospective, observational study to assess the clinical efficacy and safety of Leflunomide as first-line therapy and as add-on therapy to other DMARDs (such as Methotrexate, Hydroxychloroquine, Sulfasalazine) with or without Steroids use in Egyptian patients with Active Rheumatoid Arthritis.
Conditions
Timeline
- Start date
- 2017-06-16
- Primary completion
- 2018-10-13
- Completion
- 2018-10-13
- First posted
- 2018-07-26
- Last updated
- 2020-06-30
- Results posted
- 2020-06-30
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT03599986. Inclusion in this directory is not an endorsement.